Mass Tort brief
Corporate Defendants Secure Historic Shields in Mass Tort Litigation
Johnson & Johnson and Monsanto land major courtroom victories that reshape thousands of talc and weedkiller cancer claims.
Mass Tort
J&J is settling its talc cancer litigation for $5.5B — exploiting weakened plaintiff expert testimony to finally buy its way out of its largest legal threat.
BackgroundTens of thousands of plaintiffs have sued Johnson & Johnson, alleging that asbestos-contaminated talc in its baby powder caused their ovarian cancer. The company previously tried to resolve these liabilities through a controversial bankruptcy maneuver known as the Texas two-step, but federal courts repeatedly rejected the strategy.
- The proposed agreement is uncapped and schedules the first major payout installment of up to $3 billion for 2027, providing a structured timeline to begin resolving claims.
- The deal follows a New Jersey multi-district litigation court order requiring plaintiffs to substantiate their expert witnesses, which weakened the plaintiffs' legal standing and forced negotiations.
- This settlement resolves only existing US state and federal cases, meaning J&J still faces future domestic claims and active lawsuits in the United Kingdom.
Mass Tort
Monsanto has secured a landmark Supreme Court preemption shield — a ruling that decimates the failure-to-warn claims of 69,000 plaintiffs and fundamentally reshapes US product liability law.
BackgroundTens of thousands of homeowners and agricultural workers have sued Monsanto, claiming exposure to its glyphosate-based weedkiller Roundup caused non-Hodgkin lymphoma. Plaintiffs have historically relied on state laws to argue the product should have carried a cancer warning, despite federal regulators repeatedly declaring the chemical safe.
- The Court ruled that EPA approval of Roundup labels without cancer warnings overrides state-level failure-to-warn requirements, effectively blocking the primary legal strategy used by personal injury lawyers.
- The decision forces plaintiffs' attorneys to pivot to alternative legal theories like manufacturing defects or design defects, which are much harder to prove in court.
- A separate $7.25 billion global class-action settlement remains on track for an August approval hearing, as it is unaffected by this preemption ruling.
Unlock the full brief
Sign in to read every signal, takeaway, and source. Free account — Apple, Google, or email.
